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ABSTRACT
Depletion of cellular energy activates the AMP-activated protein kinase (AMPK) 
to favor energy-producing catabolic processes during tumorigenesis. Using a panel 
of in vitro cell lines and resected tumors, we investigated the therapeutic value 
of manipulating AMPK in prostate cancer (PC). Phospho-AMPK expression was 
significantly elevated in human PC cells and clinical PC samples. In clinical PC, 
we observed a trend for increasing phospho-AMPK with increasing Gleason sum 
score; Phospho-AMPK expression was associated with phospho-ACC (p=0.0023). 
Using the paired PC3 and PC3M cells to model progressive androgen-independent 
PC, treatment with either 5-aminoimidazole-4-carboxamide riboside (AICAR) or 
A-769662 suppressed proliferation, migration and invasion in both cell lines, and 
down-regulated mTOR and P70S6Ki levels regardless of the Akt status. Involvement 
of AMPK was confirmed by Compound C (AMPK inhibitor) and siRNA-mediated AMPK 
silencing. Despite similar functional responses in PC3 and PC3M cells, AMPK activation 
resulted in sustained phospho-Akt activation in PC3M cells, but not in PC3 cells. 
This prompted the addition of the PI3K inhibitor LY-294002 to AICAR treatment of 
PC3M cells in a proliferation assay. Interestingly, we found no synergistic effects 
upon combined treatment. Collectively, these findings support AMPK as a potential 
therapeutic target independent of PI3K/Akt signalling.
INTRODUCTION
The AMP-activated protein kinase (AMPK) is a 
cellular energy sensor comprising of a catalytic α subunit 
and regulatory β and γ subunits [1]. It is activated in 
response to metabolic stresses that increase the AMP/
ATP ratio either by increasing the consumption of ATP or 
interfering with the catabolic production of ATP [1]. 
AMPK is activated when phosphorylated at Thr172 
on the α subunit [1]. Two AMPK kinases have been 
identified that phosphorylate AMPKα Thr172, namely 
liver kinase B1 (LKB1) and Ca2+/calmodulin-dependent 
protein kinase kinase β (CaMKKβ) [2, 3]. Increased 
AMP:ATP allosterically activates AMPK (binding to 
the AMPKγ subunit) and inhibits dephosphorylation of 
Thr172 in the presence of constitutive LKB1 activity. 
The precise phosphatase that inactivates AMPK in vivo 
remains uncertain [4]. In cells expressing CaMKKβ, 
increased intracellular Ca2+ concentrations activate AMPK 
independent of changes in AMP:ATP [3].  Agents that 
activate AMPK include metformin and phenformin, which 
increase the AMP:ATP ratio, the nucleoside AICAR, 
which is metabolised to an AMP mimetic, and A769662, 
which is a direct activator of AMPK [5]. Once activated, 
AMPK phosphorylates multiple downstream catabolic 
targets to promote fatty acid oxidation and glucose uptake, 
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while anabolic processes such as fatty acid synthesis and 
protein synthesis tend to be suppressed [4].
The malignant phenotype in cancer is characterised 
by increased synthesis of lipid, DNA and protein synthesis 
as well as enhanced proliferation and migration; AMPK 
has been shown to be a key regulator of these events 
[6]. In addition, AMPK can regulate apico-basal cellular 
polarity of the epithelium, and also directly interact 
with components of the cell cycle machinery such as 
centrosomes and spindle poles to control the cell cycle 
[7, 8]. Cell migration can also be directly controlled by 
AMPK-mediated phosphorylation of the microtubule plus 
end protein CLIP-170 [9].
The phosphatidylinositol 3’-kinase (PI3K) signaling 
network plays critical roles in the regulation of cell 
growth, proliferation, differentiation, motility, survival 
and intracellular trafficking. The PI3K/Akt pathway 
exhibits extensive cross-regulatory interactions with the 
intermediate metabolism network, including AMPK, to 
fuel resistance to stress and uncontrolled growth [10]. Akt 
has been reported to dramatically reduce the AMP/ATP 
ratio and suppress AMPK activity in cells overexpressing 
a constitutive Akt mutant [11]. In addition, Akt may 
directly mediate inhibitory phosphorylation of AMPKα1/
α2 at Ser485/491 [12]. AMPK may in turn modulate the 
PI3K pathway in a complex manner, stimulating PI3K/
Akt activity and inhibiting mTOR/S6K [13]. mTOR is a 
component of mTORC1 (mammalian Target of rapamycin 
Complex 1), which is a key regulator of cell growth, 
controlling protein synthesis, ribosome biogenesis and 
autophagy through downstream effectors such as 4EBP1 
and S6K1 [14]. In addition to mTOR-mediated regulation 
of the cell cycle, the mTOR pathway responds to changes 
in the energy status of the cell, through inhibition of 
mTORC1 by AMPK [15]. Hence, AMPK/mTOR crosstalk 
may have potential implications in cancer therapies. 
Patients receiving metformin for its hypoglycaemic 
effects are thought to have a reduced risk of developing 
cancer [6]. Metformin has in vitro anti-proliferative effects 
on several tumor types including breast, prostate, ovarian, 
colon and pancreas [6]. However, the role of AMPK in 
prostate cancer (PC) remains to be fully characterised, 
with significant discrepancies in the literature. In DU145 
cells, a human PC line with activated Akt and upregulated 
glycolysis, AICAR-mediated AMPK activation suppressed 
proliferation without evidence of increased apoptosis 
[16]. Supporting a tumor-suppressing role, a dominant 
negative AMPK mutant or silencing AMPK expression 
enhanced proliferation, migration and anchorage 
independent growth in C4-2 cells, a derived sub-line from 
human LNCaP PC cells [3]. In contrast, consistent with 
a tumor-promoting role for AMPK, ~40% of clinical PC 
showed upregulated levels of phosphorylated acetyl CoA-
carboxylase (ACC), which signifies increased AMPK 
function, while inhibition or depletion of AMPK impaired 
proliferation and promoted cell death [17]. 
Given the complex nature of AMPK and PI3K 
signaling and potential crosstalk between these key 
pathways, we applied in vitro cell models and resected 
prostate tumors to investigate the role of AMPK and PI3K 
signaling in prostate cancer. 
RESULTS
In vitro and in vivo analysis of the AMPK and 
PI3K/mTOR pathways in prostate cancer (PC)
The status of AMPK and PI3K/mTOR pathways was 
highly varied in a panel of human PC cell lines (Fig. 1A). 
The highly aggressive PC3M and hormone-independent 
LNCaP-AI cells exhibited higher levels of AMPK (both 
total and phosphorylated) and its substrate ACC relative 
to the parental PC3 and LNCaP cells, respectively. The 
variation in phospho-AMPK was independent of the 
level of the upstream kinase LKB1, which was expressed 
at similar levels in all cell lines except in the LKB1-
deficient DU145 cells. While the level of total Akt 
was higher in PC3M cells than in PC3, there was more 
phospho-Akt in PC3 cells than PC3M cells, suggesting 
preferential activation of Akt in PC3 cells compared 
to PC3M cells. This variation in activation of Akt was, 
however, not observed between LNCaP and LNCaP-AI 
cells. Correlating to the phospho-Akt status, the levels 
of phosphorylated mTOR and its downstream effector 
p70S6K1 (along with the isoform p85S6K1) were lower 
in PC3M cells than in PC3 cells. In order to investigate 
the functional significance related to differences in AMPK 
and PI3K/mTOR pathways between PC3 and PC3M cells, 
subsequent in vitro experiments in this study focused on 
PC3 and PC3M cells. 
Incubation of PC3 or PC3M cells with either 
AICAR or A-769662 upregulated the levels of AMPK 
and ACC phosphorylation (Fig. 1B, C, D). AMPK 
activation was associated with differential patterns of Akt 
phosphorylation between PC3 and PC3M cells. While 
incubation with AICAR for 2 h upregulated phospho-Akt 
in both PC3 and PC3M cells (Fig. 1B), longer treatment 
with AICAR for 24 h revealed distinct responses, with 
similar observation made following A-769662 treatment 
for 1 h: Akt phosphorylation was stimulated in PC3M cells 
but attenuated in PC3 cells (Fig. 1 C, D). Furthermore, 
in PC3M cells, A-769662 treatment (50 µM) increased 
phospho-Akt, while the higher dose of A-769662 at 100 
µM reduced phosphorylation of Akt (Fig. 1D). AICAR 
and A-769662 downregulated phospho-mTORSer 2448 in 
both PC3 and PC3M cells, and, interestingly, total mTOR 
was downregulated in PC3M cells following AICAR 
treatment (24 h). Concomitant suppression of p70S6K1 
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Figure 1:Analysis of the AMPK and PI3K pathways in prostate cancer in vitro and in vivo. (A) Lysates from the indicated 
prostate cancer cell lines were immunoblotted for phosphorylated and total AMPKα, ACC, Akt, mTOR and p70S6K1 proteins. PC3M and 
LNCaP-AI were derived from PC3 and LNCaP parental cells, respectively. (B, C, D, E) Whole cell lysates were prepared from PC3 and 
PC3M cells maintained in serum free medium and treated with (B) AICAR (500 and 2000 µM) for 2 h, (C) AICAR (500 and 2000 µM) 
for 24 h, (D) A-769662 (50 and 100 µM) for 1 h, and (E) Compound C (5 µM and 10 µM) for 2 h. (F) Representative images showing 
phospho-AMPKα and phospho-ACC in clinical prostate tumors with (i) high Histoscore (H-Score) for both p-AMPKα and P-ACC and (ii) 
low H-Score for phospho-AMPKα but high H-Score for phospho-ACC. (Scale bar=100 µm). (G) Trend for increasing phospho-AMPKα 
immunoreactivity with tumors with high Gleason sum score (<7, 7 and >7), with statistically significant difference between Gleason 8 or 
higher to Gleason <7 (p=0.0251, Mann-Whitney test). [(B, C, D, E)]. Values under Western blots represent level of each protein normalized 
to GAPDH or α-tubulin. Western blots (panels A-E) are representative of three independent experiments.
Oncoscience449www.impactjournals.com/oncoscience
and p85S6K1 phosphorylation was observed following 
AMPK activation (Fig. 1B, C, D). 
To validate the specific nature of our AMPK 
activators, Compound C (CC), a cell-permeable 
pyrrazolopyrimidine compound, was used as a reversible 
ATP-competitive inhibitor of AMPK [18]. As expected, 
Compound C suppressed the steady state of both AMPK 
and ACC phosphorylation in normal culture conditions 
(Fig.1E), along with decreased phospho-Akt and increased 
phospho-mTOR levels. 
Studying AMPKα and ACC phosphorylation status 
in vivo, a tissue microarray (TMA) of resected clinical PC 
was studied by immunohistochemistry (Fig.1F). Overall, 
when compared to benign prostate hyperplasia (BPH), 
PC showed upregulated expression for phospho-AMPKα 
and phospho-ACC, with mean histo-score of 19.39 
(range 0-160, n=123) and 33.61 (range 0-270, n=102) 
respectively, contrasting with mean histoscore of zero 
for both phospho-AMPKα and -ACC in BPH samples. 
Phospho-AMPK immunoreactivity was significantly 
higher in poorly differentiated tumors (Gleason score 
8 or above) than low grade tumors (Gleason score <7), 
p=0.0251, Mann-Whitney test (Fig. 1G). There was 
also a significant positive correlation between phospho-
AMPKα and phospho-ACC levels (Spearman correlation 
coefficient = 0.4588; P = 0.0003). Interestingly, in 
some tumors, we observed significant phospho-ACC 
immunoreactivity despite low phospho-AMPKα levels 
(Fig. 1Fii). 
Analysis of AMPK-mediated functions in PC in 
vitro
AMPK activation by AICAR (500 µM and 2000 
µM) or A-769662 (50 µM and 100 µM) significantly 
suppressed proliferation in both PC3 and PC3M cells 
in a dose-dependent manner, regardless of the extent of 
serum supplement in the culture medium (Fig. 2A-D). 
Interestingly, when cultured in full medium supplement, 
proliferation of PC3M cells was significantly diminished 
by A-769662 only at higher concentrations (200 and 
300 µM). The involvement of AMPK in the observed 
anti-mitogenic effects was supported by: (1) Compound 
C (CC) treatment, at least partially, rescued both PC3 
and PC3M cells from AICAR-induced suppression of 
proliferation (Fig. 2E); (2) Importantly, siRNA-targeting 
AMPKα1 abolished AICAR induced anti-proliferative 
effects (Fig. 2F). In PC3 cells, knockdown of AMPK 
expression has an overall mitogenic effect despite the 
presence of AICAR; and (3) Treatment with either CC 
(Fig. 2E,S1) or siRNA-mediated silencing of AMPKα1 
expression did not suppress proliferation (Fig. 2F). 
Following siRNA-mediated AMPK knockdown, both 
total and phosphorylated states of AMPK and ACC were 
suppressed. Contrast to treatment with AMPK activators, 
AMPK knockdown did not increase the level of phospho-
Akt, which was either unchanged or reduced following 
AMPK gene silencing.(Fig. 2G).
Contrast to a dominant G1 cell fraction in the control 
PC3 and PC3M cells, AICAR or A-769662 treatment 
significantly shifted the cell cycle profile towards the 
G2/M phase (Fig. 3A,B for AICAR; 3E,F for A-769662, 
respectively). Anti-proliferative effects of AMPK 
activators (AICAR or A-769662) were not associated 
with apoptosis, signified by the absence of caspase-3 
or PARP cleavage products (Fig. S2). The addition of 
CC reversed the effects of both AICAR and A-769662 
(except for AICAR at the high dose of 2000 µM which 
probably reflects off-target effects). We also observed 
cyclin B1 accumulation following AMPK activation, 
which is consistent with G2/M arrest (Fig. 3C, D; 3G, H). 
CC treatment alone appeared to have the reverse effect 
and diminished cyclin B1 expression (Fig. S3A), while 
siRNA-mediated knockdown of AMPKα1 in isolation 
resulted in either reduced or mostly unchanged cyclin B1 
levels (Fig. S3B).
As PC3M cells represent an aggressive isogenic cell 
line derived from PC3 cells, we investigated the effect 
of AMPK activation on cellular motility and invasion. 
In a scratch wound assay, AMPK activation by AICAR 
significantly suppressed migration of both PC3 and PC3M 
cells in a dose-dependent manner (Fig. 4A, B; S4A, B). 
Similar results were obtained in a transwell migration 
assay (Fig. 4C; S4C). Studying in vitro invasion through 
matrigel-coated membranes, AICAR treatment inhibited 
PC3 and PC3M cellular invasion in a dose-dependent 
manner; PC3M cells appeared to be less responsive to 
AICAR at 500 µM than PC3 cells (Fig. 4D; S4D). For 
PC3 cells, AMPKα1-targeting siRNA enhanced both 
migration and invasion (Fig. 4 E, F). Interestingly, while 
PC3M cells were less responsive to AICAR treatment, 
impact of AMPK gene silencing was also more varied. 
Taken together, despite differences in the duration of 
phospho-Akt activation in PC3 and PC3M cells following 
AMPK activation, both cell lines responded similarly to 
AICAR treatment with reduced proliferation, migration 
and invasion.
AMPK-mediated anti-proliferative effect in 
PC3M cells is independent of PI3K/Akt signaling
To test the significance of phospho-Akt induction 
by AICAR (Fig. 1B, C), AICAR treatment was combined 
with the PI3K inhibitor LY-294002 in a proliferation 
assay using PC3M cells (Fig. 5). As expected, either 
AICAR or LY-294002 alone suppressed proliferation in 
PC3M cells (Fig. 5A). However, combined AICAR and 
LY-294002 treatment did not produce additional anti-
proliferative effects on PC3M cells. LY-294002 treatment 
alone increased both AMPK and ACC phosphorylation 
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Figure 2: Treatment with AICAR or A-769662 suppressed proliferation in PC3 and PC3M cells. Cell proliferation assay of 
PC3 and PC3M cells following treatment with (A, B) AICAR (500 and 2000 µM) or (C, D) A-769662 (50-300 µM); panels A, C for serum 
free medium and panels B, D for serum-supplemented medium. (E) Proliferation assay of PC3 and PC3M cells following treatment with 
AICAR (2000 µM) and Compound C (10 µM) alone or in combination, in serum free medium. Data presented in panels A-E are the values 
for mean ± SD of cell viability respective to (DMSO) control from three independent experiments, each with three technical replicates. For 
A through E * indicates significant difference at P ≤ 0.001, # at P ≤ 0.005, ▲ at P ≤ 0.01 and ▼at P ≤ 0.05 from respective control. (F) PC3 
and PC3M cells were incubated with siRNA targeting AMPKα1 alone or with AICAR (2000 µM) prior to cell proliferation assays. Data are 
presented as mean ± SD of cell viability respective to non-targeting, NT siRNA control from two independent experiments, each with three 
technical replicates. (G) Whole cell lysates were prepared from PC3 and PC3M cells following incubation with siRNA targeting AMPKα; 
Values under Western blots represent level of each protein normalized to GAPDH. Western blots are representative of two independent 
experiments.
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in a dose-dependent manner, and, as a result of PI3K 
suppression, abolished Akt and mTOR phosphorylation 
(Fig.5B). In the presence of LY-294002 treatment, the 
effects of AICAR on Akt/mTOR phosphorylation were not 
observed. Hence, AICAR-induced phospho-Akt activation 
(Fig. 1B & C) did not appear to have a pro-survival effect 
and may merely reflect a compensatory response or an off-
target effect (Fig. 5 A).
DISCUSSION
To date, the role of AMPK in prostate cancer (PC) 
remains unclear [6]. In this study, while phospho-AMPK 
and phospho-ACC immunoreactivities were significantly 
upregulated in resected PC, particularly in high-grade 
tumors, in vitro activation of AMPK resulted in tumor-
suppressing effects (reduced proliferation, migration and 
invasion) regardless of the background AMPK status and 
culture conditions (with and without serum supplement). 
In clinical PC, the presence of high phospho-ACC without 
correspondingly elevated phospho-AMPK level may 
suggest AMPK-independent phosphorylation of ACC, 
reduced ACC phosphatase activity or significant allosteric 
activation of AMPK. Consistent with enhanced phospho-
Figure 3: Treatment with AICAR or A-769662 induced G2/M arrest in PC3 and PC3M cells and cyclin B1 accumulation. 
(A, B, E, F) Cell-cycle profile analysis in (A, E) PC3 and (B, F) PC3M cells treated with (A, B) AICAR (500 and 2000 µM) or (E, F) 
A-769662 (50 and 100 µM) in the presence or absence of Compound C (10 µM). Data of cell-cycle profile analysis were presented as mean 
± SD. * indicates significant difference at P ≤ 0.001, # at P ≤ 0.005 and ▲ at P ≤ 0.01. (C, D, G, H) Western blot of whole cell lysates from 
(C, G) PC3 and (D, H) PC3M cells treated with (C, D) AICAR (500 and 2000 µM) for 2 h and 24 h or (G, H) A-769662 (50 and 100 µM) 
for 1 h, probed for cyclin B1 protein. Values under Western blots represent level of each protein normalized to GAPDH.
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Figure 4: Treatment with AICAR suppressed migration and invasion in PC3 and PC3M cells. (A, B) Wound healing assay 
by time-lapse microscopy showing migration of (A) PC3 and (B) PC3M cells in serum free medium in the presence or absence of AICAR 
(500 and 2000 µM). Data are presented as mean ± SD of three independent experiments. (C, D) Transwell assay using PC3 and PC3M 
cells for (C) migration or (D) invasion in the presence of AICAR (500 and 2000 µM) relative to (DMSO) control. (E) Migration of PC3 
and PC3M cells through insert membranes in a transwell migration assay after siRNA-mediated knockdown of AMPKα1, relative to those 
treated with non-targeting siRNA (control), over a period of 21 h. (F) Invasion of PC3 and PC3M cells through Matrigel coated membranes 
in a transwell invasion assay after si-RNA mediated knockdown of AMPKα1 over a period of 21 h (non-targeting siRNA = control). Scale 
bar = 100 µM. Three independent experiments were performed for migration and invasion of PC3 and PC3M cells. Data are presented as 
mean ± SEM of three independent experiments. * indicates significant difference at P ≤ 0.001, # at P ≤ 0.005, ▲ at P ≤ 0.01 and ▼at P ≤ 
0.05 from respective control.
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AMPK status in PC, AMPK mRNA expression was also 
found to be altered in 42 of 131 (or 32%) primary tumours 
with mRNA, majority of which showed upregulated 
AMPK expression (Figure S5).
Using isogenic pairs of human PC cells derived 
from PC3 and LNCaP cell lines, we found increasing 
levels of phospho-AMPK and phospho-ACC in the 
aggressive PC3M and LNCaP-AI sub-cells, supporting 
the association between high phospho-AMPK levels in 
aggressive clinical disease. We also characterised the 
impact of chemical activation of AMPK on the PI3K/
Akt/mTOR signaling pathway. Comparing PC3 and 
PC3M cells, phosphorylation of Akt by AMPK agonists 
(AICAR or A-769662) was more sustained in PC3M cells. 
Despite this difference between PC3 and PC3M cells, 
functional analyses for cellular proliferation, cell cycle 
profile, migration and invasion showed broadly similar 
responses in both cell lines upon AMPK activation or 
suppression. Overall, our data suggest AMPK-mediated 
effects to be independent of phospho-Akt. Besides the 
PI3K/Akt pathway, another actionable interaction has been 
suggested: AMPK inhibition in DU145 cells enhanced 
Fas-induced apoptosis via ubiquitination-mediated 
proteasomal degradation of c-FLIP, an apoptosis inhibitory 
protein [20]. 
Accepting the limitation of chemical modulators of 
AMPK with evidence of non-specific and off-target effects 
for both AICAR and Compound C [21, 22, 23], data from 
our siRNA-mediated silencing of AMPK support the 
involvement of AMPK in our phenotypic observations. 
Activation of AMPK by either AICAR or A-769662 
downregulated phospho- mTOR and phospho-p70S6K, 
irrespective of Akt phosphorylation in a non-canonical 
manner [15]. Park et al have previously suggested that 
the decreased proliferation in response to AICAR resulted 
from non-specific effect on nucleotide metabolism [24]. 
In keeping with AMPK’s role as a metabolic sensor, anti-
mitotic effects following AICAR activation was associated 
with suppressed de novo fatty acid synthesis, evidenced 
by reduced ACC and fatty acid synthase expression along 
with lower levels of the ACC product malonyl CoA [25]. 
AMPK activation has been reported to upregulate 
the p53–p21 axis to bring about cell cycle arrest [26]. 
Interestingly, we observed that AMPK activation by 
AICAR or A-769662 induced G2/M arrest in the p53-
null PC3 and PC3M cells, with the AMPK inhibitor 
Compound C at least partially reversed this effect. AICAR 
or A-769662 mediated AMPK activation was associated 
with upregulated cyclin B1 expression in a time- and dose-
dependent manner. The failure of cyclin B1 to fall may 
prevent progression through the G2/M checkpoint [27]. 
We observed no evidence of enhanced apoptosis in PC3 
and PC3M cells upon AMPK activation, consistent with 
that previously reported [16]. 
PC3 cells (and the derived aggressive PC3M cell 
line) are negative for the tumor suppressor PTEN, a 
critical negative regulator of the PI3K pathway, leading 
to constitutive Akt activity [28]. In our study using PC3 
and PC3M cells, different AMPK activators (AICAR or 
A-769662) induced phospho-Akt for different durations 
in the cell lines (Figure 1). Simultaneous AICAR and LY-
294002 (PI3K inhibitor) treatment in PC3M cells did not 
Figure 5: Treatment with AICAR or LY-294002 alone 
or in combination in PC3M cells. (A) Cell proliferation 
assay for PC3M cells treated with AICAR (2000 µM) or LY-
294002 (50 and 100 µM) alone or in combination, for 24 h, 48 h 
and 72 h respectively. Data are presented as mean ± SD relative 
to viability at the start of the assay. (B) Western blot analysis 
of PC3M cells treated with the indicated concentrations of 
AICAR or LY-294002 alone or in combination for 24 h. Values 
represent levels of each protein normalized to GAPDH. The 
blots are representative of Western blots from three independent 
experiments.
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result in additional reduction of proliferation. Therefore, 
induction of phospho-Akt by AMPK is unlikely to have 
a major role as a pro-survival signal. Since A-769662 is 
reported to be a more efficient activator of AMPK [29], 
differences in the profile of phospho-Akt following 
treatment with AMPK-activators (AICAR or A-769662) 
may reflect the pharmacodynamics of these agents, with 
a relatively slower response to AICAR when compared to 
A-769662. Prior to formal exploitation of AMPK targeting 
therapy in PC in the future, it is therefore necessary to 
probe for relevant interactions between networks driving 
invasive PC. 
MATERIALS AND METHODS
Cell culture and treatment
Human prostate cancer cell lines CWR22, DU-145, 
PC3, PC3M, LNCaP, and LNCaP-AI were authenticated 
by LCG standards. Cells were grown in RPMI 1640 
medium (Gibco) containing 10 % (v/v) serum supplement 
and 2 mM L-Glutamine in a humidified incubator (37°C 
and 5 % CO
2
). All incubations in the presence or absence 
of various compounds or siRNA were performed in a 
humidified incubator (37°C and 5 % CO
2
). The AMPK 
inhibitor Compound C {6-[4-(2-Piperidin-1-yl-ethoxy)-
phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine} was 
obtained from Calbiochem and stored as a 10 mM solution 
in DMSO at 2-8°C, until further use. Prior to treatment, 
sub-confluent cultures of PC3 and PC3M cells were 
incubated in serum free medium comprising RPMI 1640 
and 2 mM L-Glutamine for 2 h, following which AICAR 
(Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, 
Sigma-Aldrich), Compound C (Calbiochem), or the 
solvent of these compounds, DMSO (control) were added 
in serum free medium and the cells incubated for 2 h and 
24 h respectively. Treatment with LY-294002 (Sigma-
Aldrich) alone or in combination with AICAR was 
performed in a similar manner for 24 h. Treatment with 
A-769662 (Abcam) was preceded by incubation of PC3 
and PC3M cells in serum free medium for 1 h, following 
which A-769662 or DMSO (control) were added, and the 
cells were incubated further for 1 h. 
si-RNA mediated knockdown of AMPKα
ON-TARGET plus PRKAA1 siRNA J-005027-
06 and J-005027-07 (referred to as siRNA #6 and #7, 
respectively, thereafter)(Dharmacon) were used for 
knockdown of AMPKα1. ON-TARGET plus non-targeting 
siRNA#1 (Fermentas) was used as a negative control. 
siRNAs were transfected into PC3 and PC3M cells in 
medium supplemented with serum using Lipofectamine 
RNAiMax (Invitrogen) according to manufacturer’s 
instructions, following which cells were incubated at 37°C 
and 5 % CO
2 
for 72 h.
Western blot analysis
Cells were lysed in lysis buffer [50 mM Tris-HCl 
pH 7.6, 150 mM sodium chloride, 1% (v/v) triton-X 
100, 0.5% (v/v) deoxycholate, 0.1% (v/v) SDS, 1 mM 
sodium orthovanadate, 5 mM sodium fluoride, 50 mg/L 
phenyl methyl sulphonyl fluoride, 1x protease inhibitor 
cocktail mix (Calbiochem) and 1x PhosSTOP (Roche)]. 
The protein samples were separated by SDS-PAGE and 
transferred to Immobilon P polyvinylidenedifluoride 
membrane (Millipore). The membranes were then blocked 
with 5% non-fat dry milk and incubated in a solution of 
specific primary antibody at dilution 1:1000. The primary 
antibodies used are listed below: rabbit anti-AMPKα 
(#2603), anti-phospho-AMPKα (Thr 172) (#2535), anti-
ACC (#3676), anti-phospho-ACC (Ser 79) (#3661), anti-
Akt (#9272), anti-phospho-Akt (Ser 473) (#4060), anti-
mTOR (#2983), anti-phospho-mTOR (Ser 2448) (#2976), 
anti-p70S6K (#9202), anti-phospho-p70S6K (Thr 389) 
(#9234) and anti-caspase 3 (#9662) antibodies from 
Cell Signaling Technology; anti-cyclin B1 from Abcam; 
mouse anti-PARP (4338-MC-50) antibody from Genzyme; 
mouse anti-α-tubulin (sc-8035) antibody from Santa 
Cruz Biotechnology and Horseradish Peroxidase (HRP)-
labeledmouse anti-GAPDH (Sigma-Aldrich). Secondary 
antibody used was HRP-labelled goat anti-rabbit IgG or 
horse anti-mouse IgG (Cell Signaling) at a dilution of 
1:5000. Chemiluminescent detection was performed using 
ECL Western Blotting Reagent (Amersham) according to 
manufacturer’s instructions.
Cell proliferation assay
PC3 and PC3M cells (5x103/well) were plated 
in a 96-well plate in triplicate, and grown in medium 
supplemented with serum for 24 h in a humidified 
incubator (37°C and 5% (v/v) CO
2
), following which the 
required compounds, DMSO (control) or siRNA were 
added, and the cells incubated for further 24, 48 or 72 h. At 
the end of the period of treatment, the numbers of viable 
cells were determined using Cell Proliferation Reagent 
WST-1 (Roche), as described by the manufacturer. 
Cell cycle analysis
PC3 and PC3M (1x106) were grown in medium 
supplemented with serum for 24 h, following which the 
compound(s) of interest or DMSO (control) were added, 
and the cells incubated for 72 h. Subsequently, the cells 
were harvested, fixed in 70 % ethanol and stained with 
propidium iodide (10µg/ml) after treatment with RNase 
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(400 µg/ml). The cell cycle profiles were acquired using 
a flow cytometer (FACSCalibur, BD) and analysed using 
Cell Quest Pro software.
Scratch wound assay
The scratch wound assay was modified from 
a previously reported protocol [18]. PC3 and PC3M 
cells were grown to a confluent monolayer in medium 
supplemented with serum, following which they were 
incubated in serum-free medium for 2 h at 37°C and 
5% (v/v) CO
2. 
Three scratches per well were made in 
the monolayer using a P250 micropipette tip. The study 
compounds or DMSO (control) were added to each well 
in serum free medium. The migration of cells into the 
wound was then visualized using a Long Term Time Lapse 
Microscope (Nikon), over a period of 21 h. 
Transwell migration and invasion assays
The assay for migration of PC3 and PC3M cells 
was performed in 24-well plates across 8 µm Cell Culture 
Inserts (BD Falcon). Briefly, 5x104/well PC3 or PC3M 
cells were suspended in serum free medium containing 
the required compounds or DMSO (control) and allowed 
to migrate across the membrane of the inserts, using 
medium supplemented with serum and containing the 
same concentration of the compounds or DMSO, as a 
chemo-attractant. Conversely, 5x104 PC3 or PC3M cells 
transfected with specific siRNA targeting AMPKα1 were 
suspended in serum free medium, and allowed to migrate 
across the membrane of the inserts using only medium 
supplemented with serum as a chemo-attractant. The cells 
were incubated in a humidified chamber at 37°C and 5% 
CO
2, 
and allowed to migrate over a period of 21 h. 
The assay for PC3 and PC3M invasion was 
performed using Biocoat Matrigel Invasion Chambers 
(BD), as described for the transwell migration assay.
Expression analysis in resected prostate cancer 
specimens
A tissue microarray (TMA) consisting of formalin-
fixed and paraffin-embedded prostate cancer (PC, n=213) 
and benign prostatic hyperplasia (BPH, n=30) samples was 
generated and used for immunohistochemical analysis. 
Briefly, with local ethical committee approval (MREC 
01/0/36), sections from the TMA were deparaffined, 
rehydrated and antigen retrieval performed by incubation 
in citrate buffer (10mM, pH 6) at 98°C, followed by 
incubation in blocking solution containing 5% (v/v) goat 
serum. Tissue sections were then incubated in solutions 
containing the relevant primary antibodies (rabbit anti-
phospho-AMPKα (Thr172) and anti-phospho-ACC (Ser79) 
antibodies) overnight at 4°C at dilutions of 1:75 and 1: 
500 respectively, followed by incubation in HRP-labelled 
secondary antibody for 1 h at room temperature (Dako 
Envision System). Negative controls were included with 
the primary antibody omitted prior to incubation in the 
secondary antibody. 3,3′-Diaminobenzidine (Ultravision 
Detection System, Thermo Scientific) was used as the 
chromogen, and hematoxylin as counterstain. The cores 
were blindly scored by two independent observers (YC 
and IA) to generate a Histoscore (H-Score), defined as 
intensity of staining, quantified as 0 for undetectable 
staining, 1 for low staining, 2 for intermediate staining 
and 3 for high staining multiplied by the area of the core 
stained with a specific intensity [19].
Statistical Analysis
All data is represented as mean ± SD, with the 
exception of data pertaining to the Transwell migration 
assay and invasion assay, which is represented as mean ± 
SEM. Statistical significance was assessed by Student’s t 
test (2-tailed). 
ACKNOWLEDGEMENTS
Hing Y Leung receives funding from Cancer 
Research UK, Medical Research Council and Prostate 
Cancer UK. Yashmin Choudhury was supported by 
Overseas Associateship funded by the Department of 
Biotechnology, Ministry of Science and Technology, 
India. Ian P Salt receives funding from the British Heart 
Foundation and Diabetes UK.
Conflict of interest
The authors declare no conflicts of interest.
REFERENCES
1. Hardie DG. AMP-activated protein kinase: a cellular 
sensor with a key role in metabolic disorders and in cancer. 
Biochem Soc Trans. 2011; 39(1): 1-13.
2. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, 
Mäkelä TP, Alessi DR, Hardie DG. Complexes between 
the LKB1 tumor suppressor, STRADalpha/beta and 
MO25alpha/beta are upstream kinases in the AMP-activated 
protein kinase cascade. J Biol. 2003; 2(4): 28.
3. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman 
AM, Frenquelli BG, Hardie DG. Calmodulin-dependent 
protein kinase kinase-beta is an alternative upstream kinase 
for AMP-activated protein kinase. Cell Metab. 2005; 2(1): 
9-19.
4. O’ Neill LA, Hardie DG. Metabolism of inflammation 
limited by AMPK and pseudo-starvation. Nature. 2013; 
Oncoscience456www.impactjournals.com/oncoscience
493(7432) :346-55.
5. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans 
A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, 
Evans AM, Hardie DG. Use of cells expressing gamma 
subunit variants to identify diverse mechanisms of AMPK 
activation. Cell Metab. 2010; 11(6): 554-65.
6. Brown KA, Samarajeewa NU, Simpson ER. Endocrine-
related cancers and the role of AMPK. Mol Cell Endocrinol. 
2013; 366(2): 170-9.
7. Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, 
Menendez JA. AMPK: Evidence for an energy-sensing 
cytokinetic tumor suppressor. Cell Cycle. 2009; 8(15): 
3679-83.
8. Nakano A, Kato H, Watanabe T, Min KD, Yamazaki S, 
Asano Y, Seguchi O, Higo S, Shintani Y, Asanuma H, 
Asakura M, Minamino T, Kaibuchi K, Mochizuki N, 
Kitazake M, Takashima S. AMPK controls the speed of 
microtubule polymerization and directional cell migration 
through CLIP-170 phosphorylation. Nat Cell Biol. 2010; 
12(6): 583-90.
9. Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, 
and autophagy networks: interactive partners in cellular 
health and disease. Annu Rev Pharmacol Toxicol. 2013; 
53: 89-106.
10. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, 
Sonenberg N, Hay N. Akt activates the mammalian target 
of rapamycin by regulating cellular ATP level and AMPK 
activity. J Biol Chem. 2005; 280(37): 32081-9.
11. Tao R, Gong J, Luo X, Zang M, Guo W, Wen R, Luo Z. 
AMPK exerts dual regulatory effects on the PI3K pathway. 
J Mol Signal. 2010; 5(1):1.
12. Hawley SA, Ross FA, Gowans GJ, Tibarewal P, Leslie NR, 
Hardie DG. Phosphorylation by Akt within the ST loop 
of AMPK-1 downregulates its activation in tumour cells. 
Biochem J. 2014; 459(2):275-87.
13. Sabatini DM. mTOR and cancer: insights into a complex 
relationship. Nat Rev Cancer. 2006; 6(9): 729-34.
14. Memmott RM, Dennis PA. Akt-dependent and -independent 
mechanisms of mTOR regulation in cancer. Cell Signal. 
2009; 21(5): 656-64.
15. Jose C, Hébert-Chatelain E, Bellance N, Larendra A, Su 
M, Nouette-Gaulain K, Rossignol R. AICAR inhibits 
cancer cell growth and triggers cell-type distinct effects on 
OXPHOS biogenesis, oxidative stress and Akt activation. 
Biochim Biophys Acta. 2011; 1807(6): 707-18.
16. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, 
Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar 
D, Brown ML, Fornace A, Dritschilo A, Collins SP.. AMP-
activated protein kinase promotes human prostate cancer 
cell growth and survival. Mol Cancer Ther. 2009; 8(4): 733-
41.
17. Valster A, Tran NL, Nakada M, Berens ME, Chan AY, 
Symmons M. Cell migration and invasion assays. Methods. 
2005; 37(2): 208-215
18. Chen Z, Wang T, Cai L, Su C, Zhong B, Lei Y, Xiang AP. 
Clinicopathological significance of non-small cell lung 
cancer with high prevalence of Oct-4 tumor cells. J Exp 
Clin Cancer Res. 2012; 31: 10.
19. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, 
Billaud M, Giri S, Andreelli F. AMPK inhibition in health 
and disease. Crit Rev Biochem Mol Biol. 2010; 45(4): 276-
95.
20. Jung SN, Park IJ, Kim MJ, Kang I, Choe W, Kim SS, 
Ha J. Down-regulation of AMP-activated protein kinase 
sensitizes DU145 carcinoma to Fas-induced apoptosis via 
c-FLIP degradation. Exp Cell Res. 2009; 315(14): 2433-41.
21. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 
5-Aminoimidazole-4-carboxamide ribonucleoside a specific 
method for activating AMP-activated protein kinase in 
intact cells? Eur J Biochem. 1995; 229: 558-65.
22. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, 
McLauchlan H, Klevernic I, Arthur JSC, Alessi DR, Cohen 
P. The selectivity of protein kinase inhibitors: a further 
update. Biochem J. 2007; 408: 297-315.
23. Liu X, Chhipa RR, Nakano I, Dasgupta B. The AMPK 
inhibitor Compound C is a potent AMPK-independent 
antiglioma agent. Mol Cancer Ther. 2014; doi: 
10.1158/1535-7163.
24. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, 
Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar 
D, Brown ML, Fornace A, Dritschilo A, Collins SP. AMP-
activated protein kinase promotes human prostate cancer 
cell growth and survival. Mol Cancer Ther. 2009; 8(4): 733-
41.
25. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-
activated protein kinase activators can inhibit the growth 
of prostate cancer cells by multiple mechanisms. Biochem 
Biophys Res Commun. 2004; 321(1): 161-7.
26. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK 
and cell proliferation-AMPK as a therapeutic target for 
atherosclerosis and cancer. J Physiol. 2006; 574: 63-71.
27. Hochegger H, Takeda S, Hunt T. Cyclin-dependent kinases 
and cell-cycle transitions: does one fit all? Nat Rev Mol Cell 
Biol. 2008; 9(11): 910-16.
28. Grünwald V, DeGraffenried L, Russel D, Friedrichs 
WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse 
doxorubicin resistance conferred by PTEN status in prostate 
cancer cells. Cancer Res. 2002; 62(21): 6141-5.
29. Göransson O, McBride A, Hawley SA, Ross FA, Shpiro N, 
Foretz M, Viollet B, Hardie DG, Sakamoto K. Mechanism 
of action of A-769662, a valuable tool for activation of 
AMP-activated protein kinase. J Biol Chem. 2007; 282(45): 
32549-60.
